A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind (opens in new tab)

Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of Estrogen Receptor-positive (ER + ) metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an “evolutionary double-bind”, where adapting to one treatment inadvertently makes cancer cells more susceptible to another treatment, would improve the effectiveness and durability of response to chemotherapy. Thi...